$CCE 2Q15 PR: Outlook FY15: CCE continues to expect diluted earnings per share to grow at upper end of range of 6-8%, free cash flow in a range of $600-650MM. Capital expenditures are expected to be approx. $325MM. Weighted average cost of debt is expected to be approx. 3% and comparable effective tax rate expected to be in a range of 27-28%.
For 2017, $ENDP expects US Generics base business revenue decline to be similar to 2016 or in the low 30% range. Generics segment sales are expected to decline in the high-single to low-double digit range. In US Generics business, $ENDP estimates to realize approx. $75MM in annual net savings and launch at least 20 products in 2017.
$EQIX agreed for the purchase of ICT-Center AG, Zurich's data center operating business in Zurich, Switzerland for less than $5MM. The agreement was signed on Feb. 1, 2017 and the acquisition is expected to close sometime in early April 2017.